These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10439572)

  • 1. Subcutaneous methadone in terminally ill patients: manageable local toxicity.
    Mathew P; Storey P
    J Pain Symptom Manage; 1999 Jul; 18(1):49-52. PubMed ID: 10439572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent subcutaneous methadone administration in the management of cancer pain.
    Centeno C; Vara F
    J Pain Palliat Care Pharmacother; 2005; 19(2):7-12. PubMed ID: 16061456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
    Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
    Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment.
    Fürst P; Lundström S; Klepstad P; Runesdotter S; Strang P
    J Palliat Med; 2018 Feb; 21(2):177-181. PubMed ID: 28792784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Zimmermann C; Seccareccia D; Booth CM; Cottrell W
    J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: subcutaneous methadone-an issue revisited.
    Vielvoye-Kerkmeer AP; van Mansom I
    J Pain Symptom Manage; 2008 Jun; 35(6):572. PubMed ID: 18411020
    [No Abstract]   [Full Text] [Related]  

  • 8. Methadone: outpatient titration and monitoring strategies in cancer patients.
    Hagen NA; Wasylenko E
    J Pain Symptom Manage; 1999 Nov; 18(5):369-75. PubMed ID: 10584461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very-high-dose methadone with minimal toxicity and inadequate pain control in a hospice patient with cancer.
    Latuga NM; Wahler RG
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):143-9. PubMed ID: 23646910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone for cancer pain: what have we learned from clinical studies?
    Soares LG
    Am J Hosp Palliat Care; 2005; 22(3):223-7. PubMed ID: 15909785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations.
    Manfredi PL; Borsook D; Chandler SW; Payne R
    Pain; 1997 Mar; 70(1):99-101. PubMed ID: 9106815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral methadone for managing chronic nonmalignant pain.
    Gardner-Nix JS
    J Pain Symptom Manage; 1996 May; 11(5):321-8. PubMed ID: 8636630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous methadone in terminally-ill patients.
    Makin MK
    J Pain Symptom Manage; 2000 Apr; 19(4):237-8. PubMed ID: 10866549
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain.
    Gagnon B; Bruera E
    J Pain Symptom Manage; 1999 Aug; 18(2):120-5. PubMed ID: 10484859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.
    Edmonds KP; Saunders IM; Willeford A; Ajayi TA; Atayee RS
    Drugs; 2020 Feb; 80(2):115-130. PubMed ID: 31820362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from parenteral to oral methadone.
    González-Barboteo J; Porta-Sales J; Sánchez D; Tuca A; Gómez-Batiste X
    J Pain Palliat Care Pharmacother; 2008; 22(3):200-5. PubMed ID: 19042849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain.
    Bruera E; Watanabe S; Fainsinger RL; Spachynski K; Suarez-Almazor M; Inturrisi C
    Pain; 1995 Aug; 62(2):141-146. PubMed ID: 8545138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the clinical use of methadone for cancer pain.
    Ripamonti C; Zecca E; Bruera E
    Pain; 1997 Apr; 70(2-3):109-15. PubMed ID: 9150283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
    J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.